Human epidermal growth factor receptor 2 (HER2) overexpression, well-documented in breast and gastric cancers as a driver of aggressive tumour biology and poor prognosis, is also significant in urothelial cancer, which has the third highest rate of HER2 overexpression among cancers [83]. Here, ERBB2 is linked to neoplasm.